Although surgical removal of oligometastases might be an option for selected patients with stage IV melanomas, the backbone of the treatment of metastatic melanoma is systemic oncological therapy with immunomodulating agents (immune check point inhibitors, ICIs) and/or BRAF-signaling route-targeted therapy. This evidence concerns the gene BRAF and melanoma.